<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6177">
  <stage>Registered</stage>
  <submitdate>5/08/2016</submitdate>
  <approvaldate>5/08/2016</approvaldate>
  <nctid>NCT02861534</nctid>
  <trial_identification>
    <studytitle>A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)</studytitle>
    <scientifictitle>A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA)</scientifictitle>
    <utrn />
    <trialacronym>VICTORIA</trialacronym>
    <secondaryid>2016-000671-25</secondaryid>
    <secondaryid>1242-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <healthcondition>Chronic Heart Failure With Reduced Ejection Fraction</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Vericiguat
Treatment: drugs - Placebo for Vericiguat

Experimental: Vericiguat - Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be uptitrated to 5 mg and to 10 mg.

Placebo Comparator: Placebo - Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be uptitrated to 5 mg and to 10 mg.


Treatment: drugs: Vericiguat
2.5, 5.0, or 10.0 mg orally once daily

Treatment: drugs: Placebo for Vericiguat
2.5, 5.0, or 10.0 mg orally once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure Hospitalization</outcome>
      <timepoint>Up to approximately 3.5 years</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to the First Occurrence of CV Death</outcome>
      <timepoint>Up to approximately 3.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to the First Occurrence of HF Hospitalization</outcome>
      <timepoint>Up to approximately 3.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to Total HF Hospitalizations (including frst and recurrent events)</outcome>
      <timepoint>Up to approximately 3.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to First Occurrence of Composite Endpoint of All-cause Mortality or HF Hospitalization</outcome>
      <timepoint>Up to approximately 3.5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to All-cause Mortality</outcome>
      <timepoint>Up to approximately 3.5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  History of chronic HF (New York Heart Association [NYHA] Class II-IV) on standard
             therapy before qualifying HF decompensation

          -  Previous HF hospitalization within 6 months prior to randomization or intravenous (IV)
             diuretic treatment for HF (without hospitalization) within 3 months.

          -  Brain natriuretic peptide (BNP) levels: sinus rhythm-= 300 pg/mL; atrial
             fibrillation-= 500 pg/mL and N-terminal pro-Brain Natriuretic Peptide (NT-proBNP)
             levels: sinus rhythm- = 1000 pg/mL; atrial fibrillation - = 1600 pg/mL within 30 days
             prior to randomization

          -  Left ventricular ejection fraction (LVEF) of &lt;45% assessed within 12 months prior to
             randomization by any method

          -  If female, is not of reproductive potential or agrees to avoid becoming pregnant while
             receiving study drug and for 14 days after the last dose of study drug by complying
             with one of the following: practice abstinence from heterosexual activity or use (or
             have her partner use) acceptable contraception during heterosexual activity.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Clinically unstable at the time of randomization as defined by either the
             administration of any IV treatment within 24 hours prior to randomization, and/or
             systolic blood pressure (SBP) &lt;100 mmHg or symptomatic hypotension

          -  Current or anticipated use of long-acting nitrates or nitric oxide (NO) donors
             including isosorbide dinitrate, isosorbide 5-mononitrate, pentaerythritol
             tetranitrate, nicorandil or transdermal nitroglycerin (NTG) patch, and molsidomine

          -  Current or anticipated use of phosphodiesterase type 5 (PDE5) inhibitors such as
             vardenafil, tadalafil, and sildenafil

          -  Current use or anticipated use of a soluble guanylate cyclase (sGC) stimulator such as
             riociguat

          -  Known allergy or sensitivity to any sGC stimulator

          -  Awaiting heart transplantation (United Network for Organ Sharing Class 1A / 1B or
             equivalent), receiving continuous IV infusion of an inotrope, or has/anticipates
             receiving an implanted ventricular assist device

          -  Primary valvular heart disease requiring surgery or intervention, or is within 3
             months after valvular surgery or intervention

          -  Hypertrophic obstructive cardiomyopathy

          -  Acute myocarditis, amyloidosis, sarcoidosis, Takotsubo cardiomyopathy

          -  Post-heart transplant cardiomyopathy

          -  Tachycardia-induced cardiomyopathy and/or uncontrolled tachyarrhythmia

          -  Acute coronary syndrome (unstable angina, non-ST elevation myocardial infarction
             [NSTEMI], or ST elevation myocardial infarction [(STEMI]) or coronary
             revascularization (coronary artery bypass grafting [CABG] or percutaneous coronary
             intervention [PCI]) within 60 days, or indication for coronary revascularization at
             time of randomization

          -  Symptomatic carotid stenosis, transient ischemic attack (TIA) or stroke within 60 days

          -  Complex congenital heart disease

          -  Active endocarditis or constrictive pericarditis

          -  Estimated glomerular filtration rate (eGFR) &lt;15 mL/min/1.73 m2 or chronic dialysis

          -  Severe hepatic insufficiency such as with hepatic encephalopathy

          -  Malignancy or other non-cardiac condition limiting life expectancy to &lt;3 years

          -  Require continuous home oxygen for severe pulmonary disease

          -  Current alcohol and/or drug abuse

          -  Participated in another interventional clinical study and treatment with another
             investigational product =30 days prior to randomization or plans to participate in any
             other trial/investigation during the duration of this study

          -  Mental or legal incapacitation and is unable to provide informed consent

          -  Immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is
             involved with this study

          -  Interstitial Lung Disease

          -  Breastfeeding or plans to breastfeed during the course of the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>20/09/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>4872</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>24/01/2020</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Merck Sharp &amp; Dohme - North Ryde</hospital>
    <postcode> - North Ryde</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Alabama</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arizona</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Delaware</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Georgia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Idaho</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Indiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maine</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Mississippi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nevada</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Wisconsin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Argentina</country>
      <state>Buenos Aires</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Austria</country>
      <state>Vienna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Belgium</country>
      <state>Brussels</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Chile</country>
      <state>Santiago</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Colombia</country>
      <state>Bogota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Czechia</country>
      <state>Prague</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Denmark</country>
      <state>Glostrup</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Finland</country>
      <state>Espoo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>France</country>
      <state>Paris</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Haar</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Alimos</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hungary</country>
      <state>Budapest</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ireland</country>
      <state>Dublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Hod Hasharon</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Rome</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Japan</country>
      <state>Chiyoda-Ku, Tokyo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Malaysia</country>
      <state>Petaling Jaya</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Mexico</country>
      <state>Mexico City</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Haarlem</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Wellington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Norway</country>
      <state>Drammen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Philippines</country>
      <state>Makati</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Warsaw</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Caguas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Humacao</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Mayaguez</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>Ponce</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Puerto Rico</country>
      <state>San Juan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Russian Federation</country>
      <state>Moscow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state>Midrand</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Madrid</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Sweden</country>
      <state>Stockholm</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Switzerland</country>
      <state>Lucerne 6</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Taipei</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Turkey</country>
      <state>Istanbul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Ukraine</country>
      <state>Kiev</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Hoddesdon</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Merck Sharp &amp; Dohme Corp.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Bayer</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Canadian VIGOUR Centre</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Duke Clinical Research Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event
      driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is
      vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the
      composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants
      with HFrEF.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02861534</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Mahesh J. Patel, MD</name>
      <address>Merck Sharp &amp; Dohme Corp.</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Toll Free Number</name>
      <address />
      <phone>1-888-577-8839</phone>
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>